Jefferies raises Nvidia stock price target to $205 on strong demand
Colleen Tupper, the Executive Vice President and Chief Financial Officer of Collegium Pharmaceutical , Inc. (NASDAQ:COLL), recently sold a portion of her holdings in the company. According to a recent SEC filing, Tupper sold 977 shares of common stock on March 14, 2025. The shares were sold at a weighted average price of $30.0034, totaling approximately $29,313. The transaction comes as Collegium demonstrates strong financial performance, with impressive gross margins of 87% and a P/E ratio of 14. InvestingPro analysis indicates the stock is currently trading below its Fair Value.
The transaction was executed as part of a pre-established Rule 10b5-1 trading plan, which Tupper adopted on August 14, 2024. Following this sale, Tupper retains 164,269 shares in the company. The sales were conducted in multiple transactions at prices ranging from $30.00 to $30.01. While this insider sale has occurred, InvestingPro data shows management has been actively buying back shares, and analysts have recently revised earnings estimates upward. For deeper insights into COLL’s valuation and growth prospects, check out the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Collegium Pharmaceutical reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.75 against the forecasted $1.66. The company also exceeded revenue projections, posting $181.9 million compared to the anticipated $179.48 million. This performance highlights a 22% year-over-year increase in net product revenues, driven by strong demand for its ADHD medication, Jornay, and pain management products, BELBUCA and Xtampza ER. Looking ahead, Collegium projects net product revenue between $735 million and $750 million for 2025, with adjusted EBITDA growth expected to exceed 10%.
Additionally, Collegium Pharmaceutical announced significant changes to its Board of Directors and executive team. Gino Santini will become the new Chairman of the Board, succeeding Michael Heffernan, who is retiring. Dr. Carlos Paya has been nominated to join the board, pending shareholder approval. On the executive front, David Dieter has been appointed as Executive Vice President, General Counsel. These leadership transitions are part of the company’s strategy for board refreshment and succession planning. The company aims to align its strategic direction with the evolving pharmaceutical landscape, as noted by the changes in its governance and management team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.